Press Release

Biosimilars market worth $43.7 billion in 2026

July, 2020

" COVID-19 Impact on Biosimilars market, size, share, growth, and forecast 2020-2026 "

Biosimilars or follow-on-biologics are the "duplicated" and authorized variants of those reference biologics that have experienced patent expiration. It is an advanced and cost effective way that expands the scope of treatment options in health care. Guidelines for biosimilars assume an essential job in keeping up the suitability and harmony among unique and biosimilars items

Biosimilars improvement and approval with reference biologics is a significant part of the general advancement and development process. Different regulatory specialists, for example, EMA and FDA effectively control Biosimilars commercialization and advancement.

The market is driven by factors such as the rising prevalence of chronic diseases such as cancer and diabetes supplement the growing demands of pharmaceutical drugs. However, market growth is limited by manufacturing complexities and resistance from biological manufacturers. Furthermore, the growth of the biosimilars market is impacted with the lack of regulatory guidelines, the reluctance of physicians to prescribed biosimilars, consumer’s brand preferences, and the high capital required for research and development.

Request for sample report @

Biosimilars market research report titled “Biosimilars Market by Product, By Manufacturing, by Indication, By Geography-vGlobal Opportunity Analysis and Industry Forecast up to 2026provides key insights regarding the Biosimilars market, the major competitors in this domain and various innovations happening to tackle the upcoming challenges in the health domain. Presently, there is high development of biosimilar drugs in the pharmaceutical industry which makes its market prosperous.

The report covers provides the in-depth analysis of the major players like Probiomed, Boehringer Ingelheim, Apotex, Fresenius Kabi, Gedeon Richter, Mabxience, Amega Biotech, Biocad, Coherus Biosciences, Stada Arzneimittel Ag, Dr. Reddy’s Laboratories, Mylan, Samsung Biologics, Amgen, Biocon, Celltrion, Teva Pharmaceutical, Eli Lilly, Pfizer, and Sandoz.

Access full report summary @

The report consists of 70+ Tables and 40+ charts depicting the in-depth market study and the impact analysis of COVID-19 by Vendor’s name. The scope of the report can be summarized as:

  • This report covers biosimilars market categorized based on Indication:
    • Autoimmune Disease          
    • Blood Disorders        
    • Infectious Disease    
    • Chronic Disorder      
    • Oncology        
    • Offsite Treatment     
    • Other Diseases
  • The report also provides market segmentation based on type of manufacturing:
    • In-House Manufacturing
    • Contract Manufacturing
  • The product-based classification covered in the report is:
    • Insulin
    • Recombinant human growth hormone (rhGH)
    • Granulocyte colony-stimulating factor
    • Interferon
    • Erythropoietin
    • Etanercept
    • Monoclonal antibodies
      •  Rituximab
      • Infliximab
      •  Adalimumab
      • Trastuzumab
    • Follitropin
    • Glucagon
    • Calcitonin
    • Teriparatide
    • Enoxaparin Sodium
  • Geography based categories covered in study are:
    • North America
    • Europe
    • Asia Pacific
    • Rest of the World

Mr. Karthick Subramani

Infoholic Research LLP

Marketing & Communication